Vectomega® is the only Omega-3 with DHA/EPA in a biologically active, phospholipid form as it naturally occurs in salmon (not chemically altered or artificially spiked) ensuring absorption and improved stability.*
• Up to 50 times more absorbable
• This phospholipid form is up to 50 times more absorbable than the triglyceride form found in fish oils
• Omega-3 fatty acids clinically studied for healthy heart, brain, skin, immune, and nervous system support*
• Unique bioactive peptides further support cardiovascular health
• Extracted by a patented chemical-free process using only natural enzymes and cold water
• Triglyceride and cholesterol free
• Exceeds both European and U.S. standards for purity – no concerns with toxins, heavy metals or contaminants
• Sustainably harvested in salmon’s natural environment
• Omega-3 fatty acids have been shown to be especially beneficial for pregnant or nursing mothers
Heavy metal analysis conducted on every batch using ICP-MS method and found to be pure and safe.
Vectomega® is unique in that it is an omega-3 fatty acid supplement in tablet form. It is extracted from the head of wild-farmed salmon, which is rich in phospholipids. Phospholipids are very effective transporters of omega 3 fatty acids (EPA and DHA), and research on Vectomega shows intracellular absorption rates 50 times higher than fish oils.
Atlantic Salmon (Salmo salar) [Phospholipids, Omega 3 [DHA (docosahexaenoic) and EPA (eicosapentaenoic)] and hydrolyzed peptides]
In an open clinical trial participants experienced significant support in healthy total cholesterol levels already within the normal range, and a 13% increase in HDL levels.*1,2 In comparison, traditional fish oil studies that have obtained similar results used a range of 3.6 g - 4 g or of fish oil/day (equating to approx. 3,400 mg a day of combined DHA and EPA). Therefore, it took over 50 times the amount of combined EPA/DHA from fish oil to achieve the same results as two tablets of Vectomega.
1. Arer M, Duclaut J. Assessment of biological and clinical effects of Vectomega among healthy volunteers. 2006; Clinique M èdical. Rennes et St Etienne, France.
2. Linder M, Fanni J, Parmentier M, Regnault P. Procede d’obtention d’une huile et d’un hydrolysat de proteins a partir d’une source marine de tissus proteiques et huile et hydrolysat de proteins obtenus par mise en oeuvre de ce procede. French patent number 2,835,703. August 15, 2003.